{
    "info": {
        "nct_id": "NCT05498220",
        "official_title": "A Phase II Trial Evaluating the Efficacy of Polatuzumab Vedotin With Rituximab, Gemcitabine, Dexamethasone, and Cisplatin (PV-RGDP) Chemotherapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma",
        "inclusion_criteria": "1. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n2. Biopsy proven diffuse large B-cell lymphoma (DLBCL) in the first relapse (biopsy can be from initial diagnosis). The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n4. Radiologic evidence of active disease within 28 days of starting trial therapy.\n5. Only one prior line of therapy.\n6. Prior cancer treatment must be completed at least 14 days prior to the start of treatment and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or start of treatment.\n7. Subjects may be eligible or ineligible for autologous stem cell transplant\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment that may put the subject at undue risk as determined by the investigator.\n2. Subjective hearing loss interfering with daily activities or evidence of greater than mild hearing loss compared to age appropriate normal on screening audiometry are excluded.\n3. Women who are pregnant or breastfeeding or who intend to become pregnant within a year of the last dose of study treatment.\n4. Subjects with a history of prior or concurrent second primary malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the study drugs are eligible for enrollment in the trial.\n5. Previous exposure to polatuzumab vedotin.\n6. History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine.\n7. Contraindication to gemcitabine or cisplatin, or dexamethasone or similar corticosteroid.\n8. Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 40%, symptomatic coronary artery disease or symptomatic arrhythmias.\n9. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation > 91% on room air.",
        "miscellaneous_criteria": "In order to participate in this study, a subject must meet all of the eligibility criteria outlined below."
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Radiologic evidence of active disease within 28 days of starting trial therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Radiologic evidence of active disease within 28 days of starting trial therapy.",
                        "criterion": "active disease (radiologic evidence)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Radiologic evidence of active disease within 28 days of starting trial therapy.",
                        "criterion": "active disease (radiologic evidence)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Radiologic evidence of active disease within 28 days of starting trial therapy.",
                        "criterion": "active disease (radiologic evidence)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Radiologic evidence of active disease within 28 days of starting trial therapy.",
                        "criterion": "active disease (radiologic evidence)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Only one prior line of therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Only one prior line of therapy",
                        "criterion": "number of prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Only one prior line of therapy",
                        "criterion": "number of prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.",
                "criterions": [
                    {
                        "exact_snippets": "Written informed consent obtained to participate in the study",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "HIPAA authorization for release of personal health information",
                        "criterion": "HIPAA authorization",
                        "requirement": {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Written informed consent obtained to participate in the study",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "HIPAA authorization for release of personal health information",
                        "criterion": "HIPAA authorization",
                        "requirement": {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Biopsy proven diffuse large B-cell lymphoma (DLBCL) in the first relapse (biopsy can be from initial diagnosis). The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.",
                "criterions": [
                    {
                        "exact_snippets": "Biopsy proven diffuse large B-cell lymphoma (DLBCL)",
                        "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Biopsy proven diffuse large B-cell lymphoma (DLBCL)",
                        "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy proven"
                        }
                    },
                    {
                        "exact_snippets": "in the first relapse",
                        "criterion": "disease relapse",
                        "requirement": {
                            "requirement_type": "relapse number",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.",
                        "criterion": "high-grade B cell lymphoma",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.",
                        "criterion": "high-grade B cell lymphoma",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "Burkitt's lymphoma"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Biopsy proven diffuse large B-cell lymphoma (DLBCL)",
                                "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Biopsy proven diffuse large B-cell lymphoma (DLBCL)",
                                "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                                "requirement": {
                                    "requirement_type": "confirmation method",
                                    "expected_value": "biopsy proven"
                                }
                            },
                            {
                                "exact_snippets": "in the first relapse",
                                "criterion": "disease relapse",
                                "requirement": {
                                    "requirement_type": "relapse number",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.",
                                "criterion": "high-grade B cell lymphoma",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Biopsy proven diffuse large B-cell lymphoma (DLBCL)",
                                        "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                                        "requirement": {
                                            "requirement_type": "diagnosis",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Biopsy proven diffuse large B-cell lymphoma (DLBCL)",
                                        "criterion": "diffuse large B-cell lymphoma (DLBCL)",
                                        "requirement": {
                                            "requirement_type": "confirmation method",
                                            "expected_value": "biopsy proven"
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.",
                            "criterion": "high-grade B cell lymphoma",
                            "requirement": {
                                "requirement_type": "exclusion",
                                "expected_value": "Burkitt's lymphoma"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "8. Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 40%, symptomatic coronary artery disease or symptomatic arrhythmias.",
                "criterions": [
                    {
                        "exact_snippets": "Symptomatic cardiac disease",
                        "criterion": "cardiac disease",
                        "requirement": {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ventricular dysfunction",
                        "criterion": "ventricular dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "left ventricular ejection fraction < 40%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "symptomatic coronary artery disease",
                        "criterion": "coronary artery disease",
                        "requirement": {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic arrhythmias",
                        "criterion": "arrhythmias",
                        "requirement": {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Symptomatic cardiac disease",
                        "criterion": "cardiac disease",
                        "requirement": {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ventricular dysfunction",
                        "criterion": "ventricular dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "left ventricular ejection fraction < 40%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "symptomatic coronary artery disease",
                        "criterion": "coronary artery disease",
                        "requirement": {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic arrhythmias",
                        "criterion": "arrhythmias",
                        "requirement": {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Previous exposure to polatuzumab vedotin.",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "9. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygenation > 91% on room air.",
                "criterions": [
                    {
                        "exact_snippets": "≤ Grade 1 dyspnea",
                        "criterion": "dyspnea",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulse oxygenation > 91% on room air",
                        "criterion": "pulse oxygenation",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 91,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "≤ Grade 1 dyspnea",
                            "criterion": "dyspnea",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1,
                                    "unit": "grade"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "pulse oxygenation > 91% on room air",
                            "criterion": "pulse oxygenation",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 91,
                                    "unit": "%"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Subjective hearing loss interfering with daily activities or evidence of greater than mild hearing loss compared to age appropriate normal on screening audiometry are excluded.",
                "criterions": [
                    {
                        "exact_snippets": "Subjective hearing loss interfering with daily activities",
                        "criterion": "subjective hearing loss",
                        "requirement": {
                            "requirement_type": "interference with daily activities",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of greater than mild hearing loss compared to age appropriate normal on screening audiometry",
                        "criterion": "hearing loss on screening audiometry",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "mild (age appropriate normal)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Subjective hearing loss interfering with daily activities",
                        "criterion": "subjective hearing loss",
                        "requirement": {
                            "requirement_type": "interference with daily activities",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of greater than mild hearing loss compared to age appropriate normal on screening audiometry",
                        "criterion": "hearing loss on screening audiometry",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "mild (age appropriate normal)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine.",
                "criterions": [
                    {
                        "exact_snippets": "History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                        "criterion": "allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                        "criterion": "allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "known sensitivity or allergy to murine",
                        "criterion": "sensitivity or allergy to murine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                                "criterion": "allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                                "criterion": "allergic or anaphylactic reaction to humanized or murine monoclonal antibodies",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "known sensitivity or allergy to murine",
                        "criterion": "sensitivity or allergy to murine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [
        {
            "identified_line": {
                "line": "In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        }
    ],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "7. Subjects may be eligible or ineligible for autologous stem cell transplant",
                "criterions": [
                    {
                        "exact_snippets": "eligible or ineligible for autologous stem cell transplant",
                        "criterion": "autologous stem cell transplant eligibility",
                        "requirement": {
                            "requirement_type": "eligibility status",
                            "expected_value": [
                                "eligible",
                                "ineligible"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Prior cancer treatment must be completed at least 14 days prior to the start of treatment and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or start of treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Prior cancer treatment must be completed at least 14 days prior to the start of treatment",
                        "criterion": "prior cancer treatment",
                        "requirement": {
                            "requirement_type": "completion interval before treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or start of treatment",
                        "criterion": "reversible acute toxic effects of prior cancer treatment regimen (other than alopecia)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior cancer treatment must be completed at least 14 days prior to the start of treatment",
                        "criterion": "prior cancer treatment",
                        "requirement": {
                            "requirement_type": "completion interval before treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to \n Grade 1 or start of treatment",
                        "criterion": "reversible acute toxic effects of prior cancer treatment regimen (other than alopecia)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "3. Women who are pregnant or breastfeeding or who intend to become pregnant within a year of the last dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "intend to become pregnant within a year of the last dose of study treatment",
                        "criterion": "pregnancy intention within 1 year of last dose",
                        "requirement": {
                            "requirement_type": "intention to become pregnant within 1 year of last dose",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "intend to become pregnant within a year of the last dose of study treatment",
                        "criterion": "pregnancy intention within 1 year of last dose",
                        "requirement": {
                            "requirement_type": "intention to become pregnant within 1 year of last dose",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Subjects with a history of prior or concurrent second primary malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the study drugs are eligible for enrollment in the trial.",
                "criterions": [
                    {
                        "exact_snippets": "history of prior or concurrent second primary malignancy",
                        "criterion": "second primary malignancy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the study drugs",
                        "criterion": "potential to interfere with safety or efficacy assessment of the study drugs",
                        "requirement": {
                            "requirement_type": "potential to interfere",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "history of prior or concurrent second primary malignancy",
                        "criterion": "second primary malignancy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the study drugs",
                        "criterion": "potential to interfere with safety or efficacy assessment of the study drugs",
                        "requirement": {
                            "requirement_type": "potential to interfere",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Contraindication to gemcitabine or cisplatin, or dexamethasone or similar corticosteroid.",
                "criterions": [
                    {
                        "exact_snippets": "Contraindication to gemcitabine",
                        "criterion": "gemcitabine",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Contraindication to ... cisplatin",
                        "criterion": "cisplatin",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Contraindication to ... dexamethasone or similar corticosteroid",
                        "criterion": "dexamethasone or similar corticosteroid",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Contraindication to gemcitabine",
                        "criterion": "gemcitabine",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Contraindication to ... cisplatin",
                        "criterion": "cisplatin",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Contraindication to ... dexamethasone or similar corticosteroid",
                        "criterion": "dexamethasone or similar corticosteroid",
                        "requirement": {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment that may put the subject at undue risk as determined by the investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal",
                                "mycobacterial",
                                "parasitic",
                                "other"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at study enrollment"
                        }
                    },
                    {
                        "exact_snippets": "that may put the subject at undue risk as determined by the investigator",
                        "criterion": "risk to subject as determined by investigator",
                        "requirement": {
                            "requirement_type": "risk",
                            "expected_value": "undue"
                        }
                    },
                    {
                        "exact_snippets": "that may put the subject at undue risk as determined by the investigator",
                        "criterion": "risk to subject as determined by investigator",
                        "requirement": {
                            "requirement_type": "determined_by",
                            "expected_value": "investigator"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}